Adachi JI, Shirahata M, Suzuki T et al (2021) Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathol 38:201–209

Article  CAS  PubMed  Google Scholar 

Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akyerli CB, Yuksel S, Can O et al (2018) Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg 128:1102–1114

Article  CAS  PubMed  Google Scholar 

Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77

Article  CAS  PubMed  Google Scholar 

Arita H, Ichimura K (2022) Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathol 39:121–129

Article  CAS  PubMed  Google Scholar 

Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79. https://doi.org/10.1186/s40478-016-0351-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bale TA, Jordan JT, Rapalino O et al (2019) Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol 21:596–605

Article  CAS  PubMed  Google Scholar 

Bell EH, Zhang P, Shaw EG et al (2020) Comprehensive genomic analysis in NRG oncology/RTOG 9802: A Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38:3407–3417

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966

Article  CAS  PubMed  Google Scholar 

Bieńkowski M, Wöhrer A, Moser P et al (2018) Molecular diagnostic testing of diffuse gliomas in the real-life setting: a practical approach. Clin Neuropathol 37:166–177

Article  PubMed  PubMed Central  Google Scholar 

Brat DJ Ed, Figarella-Branger D, et al. (2021) Gliomas, glioneuronal tumours, and neuronal tumours. In: Board Wcote (editor) Central nervous system tumours 5th edn. International Agency for Research on Cancer pp 15–187

Brito C, Azevedo A, Esteves S et al (2019) Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer 19:968. https://doi.org/10.1186/s12885-019-6177-0

Article  PubMed  PubMed Central  Google Scholar 

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498

Article  Google Scholar 

Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan AK, Shi ZF, Li KK et al (2022) Combinations of single-gene biomarkers can precisely stratify 1028 adult gliomas for prognostication. Front Oncol 12:839302. https://doi.org/10.3389/fonc.2022.839302

Article  PubMed  PubMed Central  Google Scholar 

Di Stefano AL, Enciso-Mora V, Marie Y et al (2013) Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol 15:542–547

Article  PubMed  Google Scholar 

Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleming JL, Pugh SL, Fisher BJ et al (2021) Long-term report of a comprehensive molecular and genomic analysis in NRG oncology/RTOG 0424: a phase II study of radiation and temozolomide in high-risk grade II glioma. JCO Precis Oncol. https://doi.org/10.1200/po.21.00112

Article  PubMed  PubMed Central  Google Scholar 

Fujimoto K, Arita H, Satomi K et al (2021) TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142:323–338

Article  CAS  PubMed  Google Scholar 

Gorovets D, Kannan K, Shen R et al (2012) IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18:2490–2501

Article  CAS  PubMed  Google Scholar 

Grogan D, Bray DP, Cosgrove M et al (2022) Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. J Neurooncol 157:187–195

Article  PubMed  PubMed Central  Google Scholar 

Hasanau T, Pisarev E, Kisil O et al (2022) Detection of TERT promoter mutations as a prognostic biomarker in gliomas: methodology, prospects, and advances. Biomedicines. https://doi.org/10.3390/biomedicines10030728

Article  PubMed  PubMed Central  Google Scholar 

Hattori N, Hirose Y, Sasaki H et al (2016) World health organization grade II-III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci 107:1159–1164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heidenreich B, Rachakonda PS, Hosen I et al (2015) TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 6:10617–10633

Article  PubMed  PubMed Central  Google Scholar 

Higa N, Akahane T, Yokoyama S et al (2022) Molecular genetic profile of 300 Japanese patients with diffuse gliomas using a glioma-tailored gene panel. Neurol Med Chir (Tokyo) 62:391–399. https://doi.org/10.2176/jns-nmc.2022-0103

Article  PubMed  Google Scholar 

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13

Article  PubMed  PubMed Central  Google Scholar 

Ichimura K (2019) TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro Oncol 21:417–418

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izquierdo C, Barritault M, Poncet D et al (2019) Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery 85:E448–E456. https://doi.org/10.1093/neuros/nyy513

Article  PubMed  Google Scholar 

Jiang C, Kong Z, Zhang Y et al (2020) Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology 62:803–813

Article  PubMed  Google Scholar 

Killela PJ, Pirozzi PC, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525

Article  PubMed  PubMed Central  Google Scholar 

Komori T (2023) Update of the 2021 WHO classification of tumors of the central nervous system: adult diffuse gliomas. Brain Tumor Pathol 40:1–3. https://doi.org/10.1007/s10014-022-00446-1

Article  PubMed  Google Scholar 

Kumari K, Dandapath I, Singh J et al (2022) Molecular characterization of IDH wild-type diffuse astrocytomas: the potential of cIMPACT-NOW guidelines. App Immunohistochem Mol Morphol 30:410–417

Article  CAS  Google Scholar 

Kuwahara K, Ohba S, Nakae S et al (2019) Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis. Brain Tumor Pathol 36:135–143

Article  PubMed  Google Scholar 

Lasica AB, Jaunmuktane Z, Fersht N et al (2021) Genomic prognosticators and extent of resection in molecularly subtyped World Health Organization grade II and III gliomas-A single-institution, nine-year data. World Neurosurg 151:e217–e233

Article  PubMed  Google Scholar 

Li J, Xue Y, Wenger A et al (2019) Individual assignment of adult diffuse gliomas into the EM/PM molecular subtypes using a TaqMan low-density array. Clin Cancer Res 25:7068–7077

Article  CAS  PubMed  Google Scholar 

Lin AL, Rosenblum M, Mellinghoff IK et al (2020) Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. Brain Pathol 30:653–660

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma S, Rudra S, Campian JL et al (2020) Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv 2:vdaa26. https://doi.org/10.1093/noajnl/vdaa126

Article  Google Scholar